Is Precision BioSciences Inc (DTIL) overvalued? · rev $68.7M
Precision BioSciences Inc (DTIL) is a biotechnology company listed on US.
This page asks whether Precision BioSciences Inc (DTIL) looks expensive on cached numbers — not a short thesis.
Latest reported DTIL revenue for 2024-12-31 was $68.7M. Net income was $7.2M. Revenue was up 41.0% from 2023-12-31 to 2024-12-31. DTIL currently screens at market cap $48.1M.
DTIL currently screens at market cap $48.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next DTIL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the DTIL stock page for the full model, not this heading.
Not investment advice.